Im, K. W. http://orcid.org/0000-0002-8939-1532
Huppert, L. A.
Malevanchik, L. http://orcid.org/0000-0002-6004-4238
Rugo, H. S. http://orcid.org/0000-0001-6710-4814
Combes, A. J.
Campbell, M. J. http://orcid.org/0000-0002-3788-9240
Krummel, M. F.
Melisko, M. E.
Funding for this research was provided by:
Marcus Foundation Grant in Precision Medicine
Marcus Grant Foundation in Precision Medicine
Article History
Received: 9 November 2022
Accepted: 3 March 2023
First Online: 7 April 2023
Competing interests
: The authors declare no competing interests but the following competing interests: Hope S. Rugo receives research support for clinical trials through UCSF, Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Astra Zeneca, Astellas, and Gilead. Also is Honoraria from Puma, Samsung, Mylan, Chugai, Blueprint, and NAPO. Matthew F. Krummel is a founder and stockholder in Pionyr Immunotherapeutics, Foundery Innovations, and is a board member and stockholder in Deciduous Therapeutics. Michelle E. Melisko reports research funding from Astra Zeneca, Novartis, KCRN Research, Puma, and Seattle Genetics. Spouse is speaker honoraria: Genentech, Gilead, Astra Zeneca, and stockholder or Merrimac.